Evidence map›Paper›PMID 36582611›Full record

ArticleFrontiers in neurology2022

Spatiotemporal scaling changes in gait in a progressive model of Parkinson's disease.

Alex M Doyle, Devyn Bauer, Claudia Hendrix, Ying Yu, Shane D Nebeck, Sinta Fergus, Jordan Krieg, Lucius K Wilmerding, Madeline Blumenfeld, Emily Lecy and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Alex M DoyleDepartment of Neuroscience, University of Minnesota, Minneapolis, MN, United States.
Devyn BauerDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Claudia HendrixDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Ying YuDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Shane D NebeckDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Sinta FergusDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Jordan KriegDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Lucius K WilmerdingDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Madeline BlumenfeldDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Emily LecyDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Chelsea SpencerDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Ziling LuoDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Disa SullivanDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Krista BrackmanDepartment of Neuroscience, University of Minnesota, Minneapolis, MN, United States.
Dylan RossDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Sendréa BestDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
Ajay VermaDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Tyler HavelDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Jing WangDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Luke JohnsonDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Jerrold L VitekDepartment of Neurology, University of Minnesota, Minneapolis, MN, United States.
Matthew D JohnsonDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, United States.
University of Minnesota · US

Funding

Deep Brain Stimulation in the Parkinsonian MonkeyR01NS037019 · NINDS · UNIVERSITY OF MINNESOTA · PI Jerrold L Vitek · 1999 to 2026
$14.5M
Neurophysiological Mechanisms Underlying Parkinsonian Motor SignsR01NS058945 · NINDS · UNIVERSITY OF MINNESOTA · PI LUKE Aaron JOHNSON, Jerrold L Vitek · 2008 to 2026
$9.6M
The Effects of Parkinsonism and Deep Brain Stimulation on Basal Ganglia-Thalamocortical Circuitry During Sleep-Wake BehaviorR01NS110613 · NINDS · UNIVERSITY OF MINNESOTA · PI LUKE Aaron JOHNSON · 2019 to 2026
$4.7M
Neuronal Activity in MC and SMA during STN and GPi DBS in the Parkinsonian MonkeyR37NS077657 · NINDS · UNIVERSITY OF MINNESOTA · PI VITEK, JERROLD L · 2018 to 2024
$4.4M
Optimizing coordinated reset deep brain stimulation for Parkinson's diseaseR01NS117822 · NINDS · UNIVERSITY OF MINNESOTA · PI WANG, JING · 2020 to 2024
$3.0M
NINDS NIH HHS R01 NS058945NINDS NIH HHS R01 NS110613NINDS NIH HHS R01 NS117822NINDS NIH HHS R37 NS077657
6 · The paper itself

Abstract

Objective: Gait dysfunction is one of the most difficult motor signs to treat in patients with Parkinson's disease (PD). Understanding its pathophysiology and developing more effective therapies for parkinsonian gait dysfunction will require preclinical studies that can quantitatively and objectively assess the spatial and temporal features of gait. Design: We developed a novel system for measuring volitional, naturalistic gait patterns in non-human primates, and then applied the approach to characterize the progression of parkinsonian gait dysfunction across a sequence of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatments that allowed for intrasubject comparisons across mild, moderate, and severe stages. Results: Parkinsonian gait dysfunction was characterized across treatment levels by a slower stride speed, increased time in both the stance and swing phase of the stride cycle, and decreased cadence that progressively worsened with overall parkinsonian severity. In contrast, decreased stride length occurred most notably in the moderate to severe parkinsonian state. Conclusion: The results suggest that mild parkinsonism in the primate model of PD starts with temporal gait deficits, whereas spatial gait deficits manifest after reaching a more severe parkinsonian state overall. This study provides important context for preclinical studies in non-human primates studying the neurophysiology of and treatments for parkinsonian gait.

Indexed as

gaitMPTPnon-human primateParkinson's diseasepressure walkway

Identifiers

PMID36582611
PMCPMC9792983
OpenAlexW4312138048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.